Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate

Moros, Alexandra; Prenafeta, Antoni; Barreiro, Antonio; Perozo, Eva; Fernández, Alex; Cañete, Manuel; González, Luis; Garriga, Carme; Pradenas, Edwards; Marfil, Silvia; Blanco Arbués, Julià; Cebollada Rica, Paula; Sisteré-Oró, Marta; Meyerhans, Andreas; Prat Cabañas, Teresa; March, Ricard; Ferrer, Laura

Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate

Mostra el registre complet Registre parcial de l'ítem

dc.contributor.author Moros, Alexandra
dc.contributor.author Prenafeta, Antoni
dc.contributor.author Barreiro, Antonio
dc.contributor.author Perozo, Eva
dc.contributor.author Fernández, Alex
dc.contributor.author Cañete, Manuel
dc.contributor.author González, Luis
dc.contributor.author Garriga, Carme
dc.contributor.author Pradenas, Edwards
dc.contributor.author Marfil, Silvia
dc.contributor.author Blanco Arbués, Julià
dc.contributor.author Cebollada Rica, Paula
dc.contributor.author Sisteré-Oró, Marta
dc.contributor.author Meyerhans, Andreas
dc.contributor.author Prat Cabañas, Teresa
dc.contributor.author March, Ricard
dc.contributor.author Ferrer, Laura
dc.date.accessioned 2023-10-09T06:26:50Z
dc.date.available 2023-10-09T06:26:50Z
dc.date.issued 2023
dc.description.abstract The continuing high global incidence of COVID-19 and the undervaccinated status of billions of persons strongly motivate the development of a new generation of efficacious vaccines. We have developed an adjuvanted vaccine candidate, PHH-1V, based on a protein comprising the receptor binding domain (RBD) of the Beta variant of SARS-CoV-2 fused in tandem with the equivalent domain of the Alpha variant, with its immunogenicity, safety and efficacy previously demonstrated in mouse models. In the present study, we immunized pigs with different doses of PHH-1V in a prime-and-boost scheme showing PHH-1V to exhibit an excellent safety profile in pigs and to produce a solid RBD-specific humoral response with neutralising antibodies to 7 distinct SARS-CoV-2 variants of concern, with the induction of a significant IFNγ+ T-cell response. We conclude that PHH-1V is safe and elicits a robust immune response to SARS-CoV-2 in pigs, a large animal preclinical model.
dc.format.mimetype application/pdf
dc.identifier.citation Moros A, Prenafeta A, Barreiro A, Perozo E, Fernández A, Cañete M, González L, Garriga C, Pradenas E, Marfil S, Blanco J, Cebollada Rica P, Sisteré-Oró M, Meyerhans A, Prat Cabañas T, March R, Ferrer L. Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate. Vaccine. 2023 Aug 7;41(35):5072-8. DOI: 10.1016/j.vaccine.2023.07.008
dc.identifier.doi http://dx.doi.org/10.1016/j.vaccine.2023.07.008
dc.identifier.issn 0264-410X
dc.identifier.uri http://hdl.handle.net/10230/58061
dc.language.iso eng
dc.publisher Elsevier
dc.relation.ispartof Vaccine. 2023 Aug 7;41(35):5072-8
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.keyword COVID-19
dc.subject.keyword Humoral immune response
dc.subject.keyword IFNγ
dc.subject.keyword RBD
dc.subject.keyword Recombinant vaccine
dc.subject.keyword SARS-CoV-2
dc.title Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate
dc.type info:eu-repo/semantics/article
dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Departament de Medicina i Ciències de la Vida)